The Real Chemistry Podcast

In this episode, Javeria Shahab, President of Medical Education at 21GRAMS, a part of Real Chemistry, discusses the challenges and changes in the medical education industry, building effective teams and the importance of empathy in healthcare communications. Get an insider's look into the industry and hear Javeria's advice for those looking to break into the field.

In this episode, Dr. Sue Desmond-Hellmann, Member of President Biden’s Council of Advisors on Science and Technology and former CEO of the Bill & Melinda Gates Foundation, Mike Huckman, Global Practice Leader of Executive Communications at Real Chemistry, and Jim Weiss, Founder and Chairman at Real Chemistry, discuss the importance of vaccination, the evolution of cancer treatments and the challenges of clinical trials. They also highlight the need for diverse representation in clinical trials, the implications of the Inflation Reduction Act on the pharmaceutical industry and the influence of science in public health and policymaking.

In this episode, Dr. Julie Gerberding, President and CEO of the Foundation for the National Institutes of Health (FNIH), Dr. Jay Bradner, FNIH board member and former President of the Novartis Institutes for Biomedical Research, and Jim Weiss, Founder and Chairman at Real Chemistry and FNIH board member, discuss the power of collaboration, how trust in science is essential for progress, emerging areas in medicine and the challenges of the current healthcare landscape. Listen to the full episode to gain valuable insights and to learn how FNIH is pioneering public-private partnerships to tackle complex health issues.

In this episode, Mark Martin, Managing Director at Houlihan Lokey, and Jim Weiss, Founder and Chairman at Real Chemistry, explore the healthcare marketing and commercialization industry, including the impact of data and technology, trends in acquisitions and deals, and the importance of organic growth and innovation.

Digital medicine is essential for improving healthcare and addressing issues related to access and equity. In the latest episode, learn about the importance of digital medicine, the challenges and opportunities in the industry and the importance of an integrated evidence plan. Plus, CEO and Co-Founder of the Digital Medicine Society (DiMe), Jennifer Goldsack, shares her thoughts on generative AI and advice for young professionals in healthcare. As part of DiMe’s upcoming Integrated Evidence Plans for Digital Health Products (IEP) project, leaders in digital health product development, regulation, reimbursement and commercial strategy will partner with payers, purchasers, policymakers, clinicians and patient groups to identify core components of an integrated evidence plan. If you would like to engage in this project and help streamline the path to regulatory and commercial success to optimize health outcomes for the greatest number of patients, learn more and share your interest to join (https://dimesociety.org/access-resources/evidence-defined/#iep-form).

Did you know that there are more than 100 types of liver diseases that affect 1.5 billion people worldwide? Join us as we explore the importance of collaboration and innovation in addressing liver health issues, the role of digital health and equity, and the future of liver health with Donna Cryer, J.D., Founder, President and CEO of the Global Liver Institute. Get the inside scoop on the latest developments in the field of liver health and how they can improve patient outcomes and access to care.